CAPITOL HILL CONSULTING GROUP

Lobbying for CLENE NANOMEDICINE · Biopharmaceutical company focused on neurodegenerative diseases,including ALS

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Utah · House · Senate · $20,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

Issues related to accelerated approval.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.